Literature DB >> 20727892

Safety of proton pump inhibitor exposure.

Yu-Xiao Yang1, David C Metz.   

Abstract

Proton pump (H(+)/K(+)-adenosine triphosphatase) inhibitors (PPIs) are widely used to treat patients with acid-related disorders because they are generally perceived to be safe and effective. However, as with any pharmacologic agent, they have the potential for side effects. Many studies have examined the side effects of long-term or short-term PPI exposure. We review the mechanism of action of PPIs, focusing on recently released products that might have greater risks of adverse effects than older products because of increased potency and/or duration of action. We summarize the data available on the putative adverse effects of PPI therapy and propose guidelines for clinicians who prescribe these agents to limit the potential for adverse outcomes in users of these effective therapeutic agents.
Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20727892     DOI: 10.1053/j.gastro.2010.08.023

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  57 in total

1.  Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients.

Authors:  Maria Meli; Maria Pia Raffa; Renato Malta; Ilaria Morreale; Luigi Aprea; Natale D'Alessandro
Journal:  Int J Clin Pharm       Date:  2015-08-30

3.  Proton pump inhibitor associated hypomagnasaemia - a cause for concern?

Authors:  Joe Begley; Trevor Smith; Kirsty Barnett; Paul Strike; Adnan Azim; Claire Spake; Tristan Richardson
Journal:  Br J Clin Pharmacol       Date:  2016-01-25       Impact factor: 4.335

4.  Balancing the risks and benefits of proton pump inhibitors.

Authors:  James M Gill; Marty S Player; David C Metz
Journal:  Ann Fam Med       Date:  2011 May-Jun       Impact factor: 5.166

Review 5.  The impact of proton pump inhibitors on the human gastrointestinal microbiome.

Authors:  Daniel E Freedberg; Benjamin Lebwohl; Julian A Abrams
Journal:  Clin Lab Med       Date:  2014-09-24       Impact factor: 1.935

Review 6.  [Duodenal ulcers, gastric ulcers and Helicobacter pylori].

Authors:  Peter Dovjak
Journal:  Z Gerontol Geriatr       Date:  2017-02-01       Impact factor: 1.281

7.  Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?

Authors:  Alexander L Fohl; Randolph E Regal
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-06-06

8.  [Long-term use of proton pump inhibitors: who needs prophylaxis?].

Authors:  M Scheurlen
Journal:  Internist (Berl)       Date:  2013-03       Impact factor: 0.743

9.  Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.

Authors:  Nobuyoshi Takabayashi; Kyoko Murata; Shiro Tanaka; Koji Kawakami
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

Review 10.  Contribution of immunomodulators to gastroesophageal reflux disease and its complications: stromal cells, interleukin 4, and adiponectin.

Authors:  Jing Li; Xiaoxin Luke Chen; Anisa Shaker; Tadayuki Oshima; Jing Shan; Hiroto Miwa; Cheng Feng; Jun Zhang
Journal:  Ann N Y Acad Sci       Date:  2016-07-21       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.